Formulary
Idursulfase: Indications, Dosing, Side Effects and Interactions
Idursulfase is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in mucopolysaccharidosis II (Hunter syndrome), a...
MedNext Academy | 3 min read
Idursulfase: Indications, Dosing, Side Effects and Interactions
Idursulfase is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in mucopolysaccharidosis II (Hunter syndrome), a...
Drug action
Idursulfase is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in mucopolysaccharidosis II (Hunter syndrome), a lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase.
Indications and dose
**Mucopolysaccharidosis II (specialist use only)**
- **Adult** (By Intravenous Infusion): 500 micrograms/kg once weekly.
**Mucopolysaccharidosis II (specialist use only) for idursulfase**
- **Child 16 months-17 years** (By intravenous infusion): 500 micrograms/kg once weekly.
Cautions
Acute febrile respiratory illness (consider delaying treatment); infusion-related reactions can occur; severe respiratory disease
Side effects
Common or very common Arrhythmias; arthralgia; chest pain; cough; cyanosis; diarrhoea; dizziness; dyspnoea; fever; flushing; gastrointestinal discomfort; headache; hypertension; hypotension; hypoxia; infusion related reaction; nausea; oedema; respiratory disorders; skin reactions; tongue swelling; tremor; vomiting Frequency not known Hypersensitivity Side-effects, further information Infusion-related reactions often occur, they can be managed by slowing the infusion rate or interrupting the infusion, and can be minimised by pre-treatment with an antihistamine and an antipyretic. Recurrent infusion-related reactions may require pre-treatment with a corticosteroid-consult product literature for details.
Interactions
**Other interactions (2):**
- No formal medicinal product interaction studies have been conducted with idursulfase.
- Based on its metabolism in cellular lysosomes, idursulfase would not be a candidate for cytochrome P450 mediated interactions.
Pregnancy
Manufacturer advises avoid.
Breast feeding
Manufacturer advises avoid-present in milk in animal studies.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Idursulfase in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

